Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Hot Drugs 2004
  • Published:

Immune and inflammatory disorders

Nature Reviews Drug Discovery volume 3, pages S19–S22 (2004)Cite this article

Brand name: Xolair Companies: Genentech/Novartis/Tanox/Sankyo Approved: 20 June 2003 Condition treated: allergic asthma Action: anti-immunoglobulin-E antibody CAS number: 242138-07-4

In the past few decades, allergic conditions such as asthma and allergic rhinitis (hay fever) have become increasingly prevalent, and are now estimated to affect ∼10–40% of the population in some industrialized countries1,2. Although these conditions are not usually life-threatening, they have a major negative effect on quality of life, and are a considerable economic burden.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mode of action of omalizumab.
Figure 2: Market for drugs to treat asthma in US $ million.

References

  1. Lundbäck, B. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 28, S2 3–10 (1998).

    PubMed  Google Scholar 

  2. Chang, T. W. The pharmacological basis of anti-IgE therapy. Nature Biotechnol. 18, 157–162 (2000).

    Article  CAS  Google Scholar 

  3. Busse, W. W. & Lemanske, R. F. Asthma. N. Engl. J. Med. 344, 350–362 (2001).

    Article  CAS  PubMed  Google Scholar 

  4. Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623–2632 (1993).

    CAS  PubMed  Google Scholar 

  5. MacGlashan, D. W. Jr et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158, 1438–1445 (1997).

    CAS  PubMed  Google Scholar 

  6. FDA Drug Approvals List [online] (cited 28 Jan 2004) <http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf> (2003).

  7. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001).

    Article  CAS  PubMed  Google Scholar 

  8. Soler, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001).

    Article  CAS  PubMed  Google Scholar 

  9. National Institute of Allergy and Infectious Disease. Fact Sheet #9: Asthma and its Environmental Triggers: Scientists Take a Practical New Look at a Familiar Illness [online] (cited 28 Jan 2004) <http://www.niehs.nih.gov/oc/factsheets/asthma.htm>

  10. Greaves, M. W. & Weinstein, G. D. Treatment of psoriasis. N. Engl. J. Med. 332, 581–588 (1995).

    Article  CAS  PubMed  Google Scholar 

  11. Krueger, J. G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1–23 (2002).

    Article  PubMed  Google Scholar 

  12. Miller, G. T. et al. Specific interaction of lymphocyte function-associated antigen with CD2 can inhibit T cell responses. J. Exp. Med. 178, 211–222 (1993).

    Article  CAS  PubMed  Google Scholar 

  13. Majeau, G. R. et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 152, 2753–2767 (1994).

    CAS  PubMed  Google Scholar 

  14. FDA Drug Approvals List [online] (cited 14 April 2004) <http://www.fda.gov/cder/foi/label/2003/alefbio013003LB.pdf> (2003).

  15. Krueger G. G. et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821–833 (2002).

    Article  PubMed  Google Scholar 

  16. Lebwohl, M. et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719–727 (2003).

    Article  CAS  PubMed  Google Scholar 

  17. Werther, W. A. et al. Humanization of an anti-lymphocyte function associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157, 4986–4995 (1996).

    CAS  PubMed  Google Scholar 

  18. Raptiva prescribing information [online] (cited 22 March 2004) <http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf> (2003).

  19. Lebwohl, M. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004–2013 (2003).

    Article  CAS  PubMed  Google Scholar 

  20. Gordon, K. B. et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290, 3073–3080 (2003).

    Article  CAS  PubMed  Google Scholar 

  21. Bielory, L. Update on ocular allergy treatment. Expert. Opin. Pharmacother. 3, 541–553 (2002).

    Article  PubMed  Google Scholar 

  22. Friedlaender, M. H. The current and future therapy of allergic conjunctivitis. Curr. Opin. Ophthalmol. 9, 54–58 (1998).

    Article  CAS  PubMed  Google Scholar 

  23. Tasaka, K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today 36, 735–757 (2000).

    Article  CAS  Google Scholar 

  24. Whitcup, S. M. et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin. Ther. 26, 29–34 (2004).

    Article  CAS  PubMed  Google Scholar 

  25. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/21565_elestat_lbl.pdf> (2003).

Download references

Additional information

Authorship This section was authored by Stephen A. Ames, Carole D. Gleeson and Peter Kirkpatrick, and includes material first published in Nature Reviews Drug Discovery. Stephen A. Ames and Carole D. Gleeson are at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA. Peter Kirkpatrick is at Nature Reviews Drug Discovery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Immune and inflammatory disorders. Nat Rev Drug Discov 3 (Suppl 7), S19–S22 (2004). https://doi.org/10.1038/nrd1408

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1408

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing